AAV Gene Therapy Pipeline Surpasses 250 Candidates as FDA Approvals and Late-Stage Trials Accelerate in 2026
核心洞察
Over 180 companies are advancing 250+ AAV-based gene therapy candidates globally, spanning preclinical through marketed stages, according to DelveInsight (搜索)'s 2026 pipeline assessment.
The FDA granted approval to Otarmeni (搜索), the first dual-AAV gene therapy for OTOF-related genetic hearing loss, and accepted Ultragenyx's BLA for UX111 in Sanfilippo syndrome Type A (搜索) with a September 2026 PDUFA date.
Taysha Gene Therapies reported FDA alignment on a BLA pathway for TSHA-102 in Rett syndrome (搜索), with pivotal REVEAL trial enrollment progressing and manufacturing validation underway.
The global pipeline for adeno-associated virus (AAV) vector-based gene therapies has expanded to encompass more than 250 therapeutic candidates from over 180 active companies, according to DelveInsight (搜索)'s "AAV in Gene Therapy Pipeline Insight, 2026" report. The assessment highlights a maturing field marked by recent FDA approvals, regulatory milestones, and advancing late-stage clinical programs across a broad spectrum of genetic disorders.
Regulatory Milestones Reshape the Landscape
April 2026 delivered two landmark events for the AAV gene therapy sector. The FDA granted approval to Otarmeni (搜索) (lunsotogene parvec-cwha), the first dual-AAV gene therapy indicated for individuals with OTOF gene-related severe-to-profound genetic hearing loss. This approval represents a significant advancement in the application of AAV-based gene therapies to sensory disorders.
In the same month, the FDA accepted the resubmitted Biologics License Application (BLA) for UX111 (rebisufligene etisparvovec), an AAV9-based gene therapy developed by Ultragenyx for the treatment of Sanfilippo syndrome Type A (搜索) (MPS IIIA). The agency assigned a Prescription Drug User Fee Act (PDUFA) target action date in September 2026, setting the stage for a potential second approval in the rare pediatric neurodegenerative disease space.
Late-Stage Clinical Progress
Taysha Gene Therapies announced in May 2026 the continued advancement of TSHA-102, an AAV-based gene therapy for Rett syndrome (搜索). The company reported that enrollment and dosing in the pivotal REVEAL trial are progressing as planned, and disclosed FDA alignment regarding its future BLA pathway. Manufacturing validation activities for TSHA-102 have been initiated to support future regulatory submissions, signaling preparation for potential commercialization.
Ultragenyx Pharmaceutical's DTX401, an investigational AAV8 gene therapy designed to deliver stable expression of G6Pase-α (搜索), is being evaluated in a Phase III clinical trial for glycogen storage disease type I (搜索). In a Phase I/II study, all nine patients demonstrated a clinical response with significant reductions in cornstarch requirements and improvements in glucose control and other metabolic parameters compared to baseline.
CSL Behring is conducting a Phase III study of AAV5-hFIXco-Padua (AMT-061), a recombinant AAV serotype 5 vector containing the Padua variant of codon-optimized human FIX cDNA, administered as a single intravenous infusion at a dose of 2 × 10¹³ gc/kg.
BioMarin Pharmaceutical initiated a Phase III, single-arm, open-label study evaluating valoctocogene roxaparvovec in Japanese patients with severe hemophilia A (搜索), while Adverum Biotechnologies advanced a Phase 3 study of Ixo-vec, a single intravitreal injection, versus aflibercept in patients with neovascular age-related macular degeneration (搜索). The primary endpoint measures mean change in best corrected visual acuity averaged at Weeks 52 and 56.
Emerging Mid- and Early-Stage Programs
Sensorion reported positive six-month results from the Phase I/II Audiogene study of SENS-501, an AAV-based gene therapy targeting otoferlin-related congenital hearing loss, showing durable efficacy trends and a favorable safety profile. The company also advanced development of GJB2-GT (SENS-601), another AAV-mediated gene therapy for genetic hearing loss, with regulatory filings anticipated in 2026.
Genethon's GNT-0003, an AAV8 vector carrying the UGT1A1 (搜索) transgene designed to correct bilirubin metabolism dysfunction, is in Phase II development for Crigler-Najjar syndrome (搜索). Rocket Pharmaceuticals' RP-A501, a recombinant AAV9 capsid delivering the LAMP2B (搜索) transgene for Danon disease (搜索), represents the first gene therapy for a cardiovascular condition to demonstrate safety and efficacy in clinical studies.
HuidaGene Therapeutics is evaluating HG202, a novel CRISPR/Cas13 RNA-targeting therapy packaged in an AAV vector, in a Phase I trial for neovascular age-related macular degeneration (搜索). The therapy targets VEGF-A (搜索) mRNA and has shown superior inhibition of choroidal neovascularization compared to aflibercept in preclinical studies.
Diverse Pipeline Across Therapeutic Areas
The AAV gene therapy pipeline spans multiple routes of administration including intravenous, intravitreal, subretinal, intracerebral, intrathecal, and intramuscular delivery. Key companies driving development include GenSight Biologics, Ultragenyx Pharmaceutical, MeiraGTx, Nanoscope Therapeutics, REGENXBIO, Astellas Gene Therapy, 4D Molecular Therapeutics, Adverum Biotechnologies, Rocket Pharmaceuticals, Passage Bio, Solid Biosciences, and Sio Gene Therapies, among others.
DelveInsight (搜索) identifies growing gene therapy approvals and clinical successes, rising prevalence of rare genetic disorders, advancements in AAV vector engineering, increasing investment, and supportive regulatory pathways as key market drivers. However, high manufacturing costs, limited AAV packaging capacity, pre-existing immunity concerns, and long-term safety questions remain significant barriers to broader adoption.